Vyome Holdings (HIND) Non Operating Income (2015 - 2026)
Vyome Holdings (HIND) posted quarterly Non Operating Income of $144419.0 for Q1 2026, up 252.06% year-over-year from $41021.3 in Q1 2025, and up 91.55% quarter-over-quarter from $75394.0 in Q4 2025.
Vyome Holdings (HIND) Non Operating Income (2015 - 2026) Analysis & Trends
Vyome Holdings' Non Operating Income history runs 12 years deep, the most recent figure standing at $144419.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 252.06% year-over-year to $144419.0; the TTM figure through Mar 2026 stood at $216823.0 (up 153.1% YoY), while the FY2025 annual figure was -$25143.0, up 94.3% from the prior year.
- Non Operating Income for Q1 2026 stood at $144419.0, up from $75394.0 in the prior quarter.
- The five-year high for Non Operating Income was $144419.0 in Q1 2026, with the low at -$266794.0 in Q3 2024.
- The 5-year median for Non Operating Income is $5000.0 (2023), against an average of -$15911.6.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income plunged 5435.88% in 2024, then jumped 350.0% in 2025.
- Vyome Holdings' Non Operating Income stood at -$160000.0 in 2022, then jumped by 110.62% to $17000.0 in 2023, then slumped by 397.36% to -$50551.0 in 2024, then soared by 249.14% to $75394.0 in 2025, then jumped by 91.55% to $144419.0 in 2026.
- Business Quant data shows HIND's Non Operating Income at $144419.0 in Q1 2026, $75394.0 in Q4 2025, and -$20990.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -53.64 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | -51.63 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 | 142,883.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142,883.00 |
| Mar 31, 2026 | 144,419.00 |
| Dec 31, 2025 | 75,394.00 |
| Sep 30, 2025 | -20,990.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | -94,976.00 |
| Dec 31, 2024 | -50,551.00 |
| Sep 30, 2024 | -266,794.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 9,000.00 |
| Mar 31, 2023 | -5,000.00 |
| Dec 31, 2022 | -160,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | 14,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | -28,000.00 |
| Sep 30, 2021 | -33,000.00 |